#74
Monitored Relevance
This is a clinically interesting randomized study in a vulnerable population, but its early termination and small sample sharply limit confidence.
A randomized, placebo-controlled design gives this paper more weight than anecdote, but the study ended early and enrolled too few patients to settle the question. For clinicians and lay readers alike, this is best read as a meaningful negative signal, not as the final word on all cannabinoid-based care in neuro-oncology.
Brain Tumors
Cannabidiol
Anxiety
Randomized Trial
| Audience | Patients, caregivers, clinicians, neuro-oncology readers |
| Primary Topic | Cannabidiol for anxiety and depressive symptoms in primary brain tumors |
| Source | Read the full article |
CBD for Brain Tumor Anxiety: What This Trial Found
CBD for brain tumor anxiety is a compelling clinical question because anxiety and depressive symptoms can meaningfully erode quality of life in patients already carrying a serious neurologic diagnosis. In this early-terminated placebo-controlled crossover randomized clinical trial, oral CBD at 600 mg/day for three weeks did not outperform placebo for anxiety or depressive symptoms in adults with stable primary brain tumors and clinically relevant anxiety at screening.
This paper asks a fair and clinically relevant question: can purified oral CBD help anxiety and depressive symptoms in adults with primary brain tumors? The answer from this specific study is no clear signal of benefit. Placebo actually showed numerically larger reductions in both anxiety and depressive symptoms, while adverse effects were broadly similar across groups. The study still teaches something important because it tests a widely discussed therapeutic idea under blinded randomized conditions, then reminds us that biological plausibility and public enthusiasm do not automatically translate into clinical improvement.
For the public: People living with brain tumors often face anxiety, low mood, uncertainty, and very understandable interest in treatments that seem gentler or more “natural.” A negative trial matters because it pushes back against the idea that CBD is automatically helpful for every distressing symptom. It also protects patients and families from spending time, hope, and money on an approach that, in this particular format and dose, did not appear to work better than placebo.
For clinicians: This paper offers a more disciplined signal than casual reports or unstructured clinical impressions. Even though the trial was small and underpowered, the direction of effect did not lean toward obvious benefit. That matters when counseling patients who ask whether purified CBD should be expected to help emotional symptoms in neuro-oncology, especially when symptom burden is complex and shaped by tumor biology, treatment effects, medications, sleep, cognition, and the stress of living with cancer.
For researchers and careful readers: This study highlights a second issue beyond efficacy, namely feasibility. Recruitment was low despite a prespecified target of 55 participants over three years, and the trial stopped early after enrolling only 20. That tells us something about the difficulty of running symptom-focused cannabinoid trials in medically fragile populations, and it means future research needs both stronger design and better practical execution.
| Study Type | Early-terminated double-blind, placebo-controlled crossover randomized clinical trial |
| Population | Adults with stable primary brain tumors and clinically relevant anxiety at screening, defined as S-STAI 44 or higher |
| Exposure or Intervention | Oral cannabidiol 600 mg/day for three weeks, greater than 99% CBD and less than 0.1% THC |
| Comparator | Matched placebo, with crossover after a washout period longer than two weeks |
| Primary Outcomes | Anxiety by S-STAI as the primary outcome, depressive symptoms by CES-D, and adverse events by CTCAE grading |
| Sample Size or Scope | 20 randomized, 15 completed both treatment periods, prespecified target 55 participants |
| Journal | Neuro-Oncology Practice |
| Year | 2026 |
| DOI | 10.1093/nop/npag025 |
| Funding or Conflicts | Investigator-initiated study funded by the Anita Veldman Foundation; authors reported no conflict of interest |
In this small crossover randomized trial, purified oral CBD did not improve anxiety or depressive symptoms in adults with primary brain tumors and clinically relevant anxiety, and placebo showed larger symptom reductions. That is a useful cautionary finding, but the early termination and limited sample mean it should guide humility more than certainty.
The investigators enrolled adults with stable primary brain tumors who had clinically relevant anxiety at screening. Participants were randomized to receive either CBD 600 mg/day or placebo for three weeks, followed by a washout longer than two weeks and then crossover to the other treatment. Anxiety was measured using the State-Trait Anxiety Inventory State Subscale, depressive symptoms with the CES-D, and adverse events with standard toxicity grading. In other words, this was not a survey about cannabis use, but a direct treatment test of purified cannabidiol under blinded conditions.
Twenty patients were randomized and fifteen completed both treatment periods. Reductions in anxiety and depressive symptoms were generally larger under placebo than under CBD. The posterior probability that CBD improved symptoms was low, reported as 19% for anxiety and 11% for depressive symptoms. Posterior median treatment differences were +1.50 for anxiety and +1.61 for depressive symptoms, values that moved away from a benefit signal rather than toward one. Clinically significant anxiety remained common after both periods, present in 50% after placebo and 59% after CBD. Adverse events were broadly similar across conditions, although one patient developed a maculo-papular rash during CBD that may have been related to a carrier substance.
On paper, a double-blind placebo-controlled randomized crossover trial sits relatively high in the evidence hierarchy for a symptom-treatment question. In practice, this study’s evidentiary strength is reduced by its early termination, very small final sample, incomplete crossover completion, and feasibility problems. So while it carries more value than anecdote or uncontrolled observation, it is still a limited randomized trial that offers a signal rather than a definitive answer.
First, the study was underpowered. The planned sample size was 55, but only 20 were randomized and only 15 completed both periods. That leaves the trial vulnerable to instability, wide uncertainty, and a real possibility that modest effects would be missed.
Second, the intervention was narrow. This was purified oral CBD at one dose, over just three weeks, in a very specific brain tumor population. It does not tell us whether different formulations, longer treatment, different dosing, combination cannabinoid approaches, or more tailored symptom targeting might perform differently.
Third, symptom outcomes such as anxiety and depression in neuro-oncology are influenced by many variables, including disease course, anticonvulsants, corticosteroids, sleep disruption, cognitive changes, and the psychological strain of serious illness. A negative result in that setting may reflect true lack of efficacy, but it may also reflect the difficulty of moving a multidetermined symptom with a single short intervention.
Finally, the authors themselves discourage further investigation in this population based on low accrual and lack of signal. That is understandable from a practical standpoint, but readers should separate feasibility failure from biological impossibility. The paper weakens enthusiasm for this exact strategy more than it closes the entire scientific conversation about cannabinoids and emotional symptoms in cancer care.
This paper does not show that all cannabinoids fail for all psychiatric symptoms in all cancer populations. It does not prove that CBD is harmful, nor does it prove that placebo is therapeutically superior in any broad sense. It also does not tell us whether some subgroups, different dosing strategies, longer treatment duration, or other symptom targets might yield different results. Most importantly, it does not justify sweeping claims either for or against cannabis-based care outside the narrow boundaries of this trial.
This early-terminated randomized trial does not support purified oral CBD as an effective short-term treatment for anxiety or depressive symptoms in adults with primary brain tumors. That does not settle every cannabinoid question in neuro-oncology, but it does meaningfully challenge easy assumptions. The most responsible takeaway is simple: hope should remain tied to evidence, and evidence should remain tied to the exact intervention, population, and outcome that were actually studied.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Frequently Asked Questions About CBD for Brain Tumor Anxiety
1. What kind of study was this?
It was a double-blind, placebo-controlled crossover randomized clinical trial, which is a stronger design than an observational report or case series for testing a treatment effect.
2. Who was included in the trial?
Adults with stable primary brain tumors and clinically relevant anxiety at screening were eligible. The enrolled group included several tumor types, not just one diagnosis.
3. What dose of CBD was tested?
Participants received 600 mg/day of oral CBD for three weeks. The study product contained greater than 99% CBD and less than 0.1% THC.
4. Did CBD improve anxiety?
Not in this trial. The data did not show a persuasive benefit, and placebo showed numerically larger reductions in anxiety symptoms.
5. Did CBD improve depressive symptoms?
No clear benefit was seen for depressive symptoms either. Again, the numerical pattern favored placebo rather than CBD.
6. Was CBD dangerous in this study?
Adverse events were broadly similar between CBD and placebo, which is somewhat reassuring. One participant developed a rash during CBD that may have been related to a carrier substance.
7. Why does early termination matter so much?
Because small, incomplete trials are less reliable. They can miss real effects, exaggerate chance findings, and make it harder to know how much confidence to place in the results.
8. Does this mean all cannabis-based care fails in brain tumor patients?
No. This study tested one purified oral CBD strategy for two symptom domains over a short period. It does not settle every cannabinoid question in oncology or neuro-oncology.
9. Why might placebo have looked better here?
Symptom studies are especially sensitive to expectation effects, natural fluctuation, regression to the mean, and contextual support. In a small trial, those factors can loom large.
10. What is the most responsible takeaway for patients and clinicians?
This study should lower confidence in expecting purified CBD to relieve anxiety or depressive symptoms in this exact setting, but it should not be stretched into sweeping claims well beyond the trial itself.
